Orlucent® has developed the first handheld fluorescent molecular imaging system to non-invasively evaluate early tissue remodeling that signals the likelihood of a mole’s transition to melanoma.
The Orlucent System evaluates biological activity originating from within the mole
The Orlucent System non-invasively determines the likelihood of malignant activity for suspicious moles to provide greater certainty in clinical assessments of indeterminate pigmented lesions.
Fluorescent biotag is topically applied then wiped away
Handheld imager captures white light and fluorescent images
The software provides a probability score for tissue remodeling
The novel Orlucent System detects a biomarker for neoangiogensis and stromal tissue remodeling associated with early melanoma development.
Fluorescent Biotag
Binds to Receptors
Imager CapturesFluorescence
Software Reports the Presence of a Malignancy Biomarker
Current mole evaluation relies heavily on visual assessment, an inherently subjective process dependent on clinician experience and interpretation. This visual and subjective approach is unfortunately not always sufficient to reliably distinguish atypical moles with malignant potential.2-4 Consequently, to overcome the limitations of this subjective visual judgment, biopsy is often used to gain more objective histopathological information. However, biopsy results are not immediate, may also be subject to interpretation, and carry some risk of infection and scarring.
Addressing physicians’ desire for improved mole evaluation tools 5-7, the Orlucent System was developed to increase accuracy in the identification of moles with the potential to become malignant. Orlucent is the first system to measure the presence of the avb3 integrin – a biological indicator for stromal tissue remodeling. By indicating the presence of tissue remodeling activity without invasive biopsy, the Orlucent System allows physicians to readily differentiate indeterminate pigmented lesions with malignant activity from those of less concern.
1. Friedman et al. The “dysplastic” nevus
2. Haenssle et al. Results of a surveillance programme for patients at high risk of malignant melanoma using digital and conventional dermoscopy
3. Annessi et al. Correlation between clinical atypia and histologic dysplasia in acquired melanocytic nevi
4. Elmore et al. Pathologists’ diagnosis of invasive melanoma and melanocytic proliferations: observeraccuracy and reproducibility study
5. March et al. Practical application of new technologies for melanoma diagnosis: Part I
6. Angelucci D. Diagnosis: Melanoma: What emerging tests and tech mean for dermatologists
7. Elmore et al. Pathologists’ diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study